08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Alexion, Prothelia, University of Nevada deal

Alexion gained an exclusive option to acquire rare disease company Prothelia, which is developing preclinical protein replacement therapy PRT-01 to treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Alexion may exercise its option upon...
01:23 , Feb 14, 2014 |  BC Extra  |  Company News

Alexion gains option to acquire Prothelia

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained an exclusive option to acquire rare disease company Prothelia Inc. (Milford, Mass.), which is developing preclinical protein replacement therapy PRT-01 to treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Prothelia...
08:00 , Jan 28, 2013 |  BioCentury  |  Emerging Company Profile

MD Pharma AB: Dialing down autophagy

With no approved drugs for congenital muscular dystrophy, patients often die in their teens. MD Pharma AB is developing autophagy inhibitors that could extend and improve quality of life for a subgroup of patients. The subtypes...